VCEL — Vericel Corporation

Summary of Vericel Corporation Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: Record $67.5 million, exceeding guidance.
• MACI Revenue: $55.7 million, up 25% year-over-year, contributing to over 20% growth year-to-date.
• Burn Care Revenue: $11.8 million, a 21% sequential increase; Epicel revenue reached $10.4 million, its highest for the year.
• GAAP Net Income: $5.1 million.
• Adjusted EBITDA: $17 million, representing a 25% margin, up nearly 800 basis points year-over-year.
• Operating Cash Flow: Record $22.1 million, with free cash flow nearing $20 million.
• Cash and Investments: Ended the quarter with $185 million.

2. Strategic Updates and Business Highlights

• MACI Growth: Continued expansion in the surgeon base and strong biopsy growth, particularly with the launch of MACI Arthro.
• Surgeon Training: Over 800 surgeons trained in MACI Arthro, with strong early indicators for growth.
• Clinical Data: Early data suggests MACI Arthro may lead to reduced postsurgical pain and faster recovery times.
• Sales Force Expansion: On track to complete the addition of 25 new territories by year-end, aimed at supporting volume growth in 2026.
• MACI Ankle Study: Phase III clinical study set to initiate in Q4 2025, expanding MACI's market potential.

3. Forward Guidance and Outlook

• Full Year Revenue Guidance: Expected total revenue of $272 million to $276 million, with MACI revenue projected at $237.5 million to $239.5 million.
• Q4 Revenue Guidance: Anticipated MACI revenue of $82 million to $84 million.
• Profitability: Full-year gross margin expected at 74% and adjusted EBITDA margin at 26%.
• Long-term Growth: Aiming for mid- to high-30% adjusted EBITDA margins by 2029, supported by sustained revenue growth.

4. Bad News, Challenges, or Points of Concern

• Burn Care Variability: Epicel's revenue is subject to variability, making precise forecasting challenging.
• NexoBrid Revenue Uncertainty: No additional revenue expected from the BARDA RFP process until government operations resume.
• Market Competition: While MACI holds a strong position, the potential for emerging competitors in the cartilage repair market remains a concern.

5. Notable Q&A Insights

• MACI Arthro Contributions: Management expects MACI Arthro to enhance overall MACI growth rather than cannibalize existing MACI sales, with positive early conversion rates noted.
• Surgeon Adoption Trends: Increased patient demand for MACI Arthro is driving surgeon interest and adoption rates.
• Seasonality in Revenue: Historically, Q1 has shown lower growth rates post-Q4; management is cautious about Q4 guidance despite strong indicators.
• R&D Investments: Anticipated increase in R&D spending next year to support the MACI Ankle trial and ongoing product development.

In summary, Vericel Corporation reported strong financial results in Q3 2025, driven by robust growth in MACI and Burn Care revenues. Strategic initiatives, particularly around MACI Arthro, are expected to sustain growth moving forward, although challenges in forecasting Burn Care revenue and potential market competition remain. The company is optimistic about its future trajectory, with solid guidance for the remainder of the year and into 2026.